# Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

Study · id `cardio:ct-nct04518306` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04518306](<https://clinicaltrials.gov/study/NCT04518306>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04518306

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 755 participants.

## Technical summary

Registry record NCT04518306. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-14 (actual); primary completion 2023-09-19 (actual). Results posted on 2025-06-03.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 755 participants (enrolled count; ClinicalTrials.gov record NCT04518306, source copy `cardio:ctgov-nct04518306-2025-06-03`, retrieved 2026-10-26)
- Started: 2021-06-14 (actual) (ClinicalTrials.gov record NCT04518306, source copy `cardio:ctgov-nct04518306-2025-06-03`, retrieved 2026-10-26)
- Primary completion: 2023-09-19 (actual) (ClinicalTrials.gov record NCT04518306, source copy `cardio:ctgov-nct04518306-2025-06-03`, retrieved 2026-10-26)
- Completion: 2023-10-18 (actual) (ClinicalTrials.gov record NCT04518306, source copy `cardio:ctgov-nct04518306-2025-06-03`, retrieved 2026-10-26)
- Results first posted: 2025-06-03 (ClinicalTrials.gov record NCT04518306, source copy `cardio:ctgov-nct04518306-2025-06-03`, retrieved 2026-10-26)
- Countries: United States; Australia; Nigeria; Sri Lanka; United Kingdom (ClinicalTrials.gov record NCT04518306, source copy `cardio:ctgov-nct04518306-2025-06-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04518306-2025-06-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension
- Acronym: GMRx2\_PCT
- Condition: Hypertension
- Intervention (Drug): Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
- Intervention (Drug): Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
- Intervention (Drug): Placebo
- Lead sponsor: George Medicines PTY Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension (`cardio:pubmed-39217570`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Long-Term Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination for the Treatment of Hypertension (`cardio:pubmed-41180852`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 57e7b2c20b8be7cc21d261b1fb5c580d764a020e6cc21f5387faa22ccb39168a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
